Circulating tumour cell (CTC) analysis could assist in target validation and patient selection for your ADC development programme. CTCs can be used in functional assays to evaluate drug efficacy and resistance mechanisms. Our patented Parsortix(R) technology ensures superior CTC enrichment for optimal downstream protein analysis, ideal for ADC development. We currently offer HER2 and PD-L1 testing, with TROP2 and PSMA assays in development, and can create custom assays specific to your clinical trial needs.
Secure your 1:1 appointment below and learn more about:
Location
San Diego, USA
Date
November 3-6, 2025
ANGLE attendees
Request a meeting with the ANGLE team at the 16th World ADC San Diego
Brett Swansiger
Chief Commercial Officer
Brett plays a key role in our global corporate partnerships and overseeing our commercial teams in their biopharma services activities and research/clinical product solutions. Brett has over 20 years of commercial leadership, international business development, and business to business sales.
Mark Rogers
Senior US Biopharma Partnering Lead
Working within ANGLE’s Biopharma Services team, Mark is focused on the United States and Canada. With over 20 years of experience in life sciences and clinical diagnostics, his expertise includes strategic pharmaceutical partnerships, diagnostic development, and clinical genomics.
Brett Swansiger
Chief Commercial Officer
Brett plays a key role in our global corporate partnerships and overseeing our commercial teams in their biopharma services activities and research/clinical product solutions. Brett has over 20 years of commercial leadership, international business development, and business to business sales.
Mark Rogers
Senior US Biopharma Partnering Lead
Working within ANGLE’s Biopharma Services team, Mark is focused on the United States and Canada. With over 20 years of experience in life sciences and clinical diagnostics, his expertise includes strategic pharmaceutical partnerships, diagnostic development, and clinical genomics.